Extended Data Fig. 3: Time-to-event analyses, including (a) DOR, (b) PFS, and (c) OS, in patients enrolled in parts 1 and 2 of COMBI-i (N = 36). | Nature Medicine

Extended Data Fig. 3: Time-to-event analyses, including (a) DOR, (b) PFS, and (c) OS, in patients enrolled in parts 1 and 2 of COMBI-i (N = 36).

From: Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

Extended Data Fig. 3

12- and 24-month DOR rates were 80% (95% CI, 59%-91%) and 53% (95% CI, 29%-73%); 12- and 24-month PFS rates were 67% (95% CI, 49%-80%) and 41% (95% CI, 23%-59%); 12- and 24-month OS rates were 86% (95% CI, 70%-94%) and 74% (95% CI, 56%-86%). DOR, duration of response; PFS, progression-free survival; NE, not estimable; OS, overall survival.

Back to article page